


ARN-21934

## Chemical Properties

CAS No. : 2230854-93-8  
 Formula: C<sub>21</sub>H<sub>24</sub>N<sub>6</sub>  
 Molecular Weight: 360.46  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	ARN-21934 is a potent, highly selective, blood-brain barrier (BBB) penetrant inhibitor for human topoisomerase II $\alpha$ over $\beta$ . It inhibits DNA relaxation with an IC <sub>50</sub> of 2 $\mu$ M, compared to 120 $\mu$ M for Etoposide. ARN-21934 exhibits favorable in vivo pharmacokinetic properties and shows promise in anticancer research, displaying affinity for topoiI $\alpha$ with an IC <sub>50</sub> of 2 $\mu$ M and for topoiI $\beta$ with an IC <sub>50</sub> of 120 $\mu$ M. It demonstrates activity against human cancer cell lines including melanoma (A375: 12.6 $\mu$ M, G-361: 8.1 $\mu$ M), breast (MCF7: 15.8 $\mu$ M), endometrial (HeLa: 38.2 $\mu$ M), lung (A549: 17.1 $\mu$ M), and prostate (DU145: 11.5 $\mu$ M) cancer cells. Following a single intraperitoneal injection of 10 mg/kg, ARN-21934 achieves a peak plasma concentration of 0.68 $\mu$ g/mL in 15 minutes, with a half-life of 149 minutes, and remains detectable in plasma and the brain for up to 360 minutes. [1] Jose Antonio Ortega, et al. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II $\alpha$ over $\beta$ . J Med Chem. 2020 Nov 12;63(21):12873-12886.
Targets(IC50)	Topoisomerase
In vitro	ARN-21934 is more potent against the $\alpha$ isoform. ARN-21934 exhibits a small panel of human cancer cell lines such as melanoma (A375, IC <sub>50</sub> = 12.6 $\mu$ M and G-361, IC <sub>50</sub> = 8.1 $\mu$ M), breast (MCF7, IC <sub>50</sub> = 15.8 $\mu$ M), endometrial (HeLa, IC <sub>50</sub> = 38.2 $\mu$ M), lung (A549, IC <sub>50</sub> = 17.1 $\mu$ M), and androgen-independent prostate (DU145, IC <sub>50</sub> = 11.5 $\mu$ M) cancer cells[1].
In vivo	ARN-21934 is able to reach the brain, with a maximum concentration of compound at 60 min, and is still present in the brain 360 min after injection. ARN-21934 (intraperitoneal injection; 10 mg/kg) reaches a maximal plasma concentration of 0.68 $\mu$ g/mL after 15 min. The half-life and clearance value are 149 min in circulation and 0.116 L/(min kg)[1].

## Solubility Information

Solubility	DMSO: 40 mg/mL (110.97 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---------------------------------------------------------------------------------------------------------------------------

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.7742 mL	13.8712 mL	27.7423 mL
5 mM	0.5548 mL	2.7742 mL	5.5485 mL
10 mM	0.2774 mL	1.3871 mL	2.7742 mL
50 mM	0.0555 mL	0.2774 mL	0.5548 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Jose Antonio Ortega, et al. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II  $\alpha$  over  $\beta$ . J Med Chem. 2020 Nov 12;63(21):12873-12886.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481